How to Tailor Formulary Exclusions Without Creating Employee Nightmares

Why Exclusions Can't Be "Set and Forget", A Real Employer's Oversight

Two years ago, I walked into a meeting with a benefits manager from a 700-employee logistics company. She had just received the annual pharmacy claims report showing spend at $128 PMPM, well above the $110 PMPM benchmark for her industry. In an attempt to rein things in, her PBM had recommended a standard list of 150 formulary exclusions for the new plan year. She agreed, eager for savings, but six months later the employee relations hotline was ringing off the hook.

What went wrong? Nearly a dozen employees couldn't fill medications they'd used for years: one lost access to a preferred migraine drug, another learned his acne prescription was non-covered, and several parents of diabetic children were told their insulin was excluded. The HR team spent weeks dealing with appeals, angry emails, and even a local news story. Net pharmacy spend dropped by $70,000, but the cost in lost productivity, employee trust, and HR fire drills far outweighed the savings.

What Excluding Drugs Actually Buys You, And What It Costs

Formulary exclusions are a blunt instrument. PBMs and consultants tout them as a way to force patients onto more cost-effective drugs. Some exclusions make sense, especially when there are therapeutically equivalent generics or biosimilars. For example, excluding brand name Adderall XR in favor of generic amphetamine salts can cut annual spend by $20,000 in a 500-life group. But go too far and employees lose access to non-interchangeable medications, driving up appeals, member dissatisfaction, and even medical costs if people skip treatment.

The financial math gets tricky. Say you're a 1,000-employee manufacturer spending $1.6 million a year on pharmacy. PBM modeling shows that excluding a block of 200 high-cost brands could cut spend by $120,000, assuming 90% of members switch to covered alternatives. But claims data shows that 15 impacted members use those brands for rare or complex diagnoses, and moving them isn't so simple. One forced switch to a non-preferred inhaler triggered an ER visit, costing the employer $9,800. Factoring in lost work time and employee complaints, "easy" savings vanish fast.

How to Tailor Exclusions: The Data-Driven Approach

Blanket PBM exclusion lists work for some jumbo employers, but mid-sized groups with under 2,000 lives can't afford collateral damage. Tailoring starts with a targeted analysis of your own claims. Pull high-cost, low-value drugs (like Vimovo or Duexis) that have clear OTC equivalents. Look for clusters where members use non-preferred brands when generics are available. Use tools like RxInfo.ai to compare net costs after rebates and member cost share.

The best interventions focus on classes where therapeutic alternatives exist and the clinical risk of switching is low. For example, in the diabetes category, excluding brand Humalog in favor of its authorized generic can save $30,000 a year on a plan with 50 diabetic members, often with zero disruption, since the authorized generic is identical. For migraine, you might limit exclusions to branded triptans when generics like sumatriptan or rizatriptan are available, but keep access to newer CGRP drugs for members who fail standard therapy.

Always run disruption analyses before finalizing exclusions. Any PBM worth their salt can show you not just projected plan savings, but which members are affected. Don't accept aggregate numbers, get a list of specific impacted drugs, with de-identified member counts. Ask your PBM or consultant to model member appeals volume, out-of-pocket increases, and clinical impact if you force switches for drugs like GLP-1 agonists (Ozempic, Wegovy) or rheumatoid arthritis biologics.

If your plan covers specialty drugs, exclusions need extra scrutiny. Excluding all but one biosimilar for adalimumab (Humira) could save $100,000 a year in a 2,000-employee company, but only if your PBM can guarantee access and clinical management for patients who must switch. Tie exclusions to enhanced clinical oversight, so a member can appeal if the preferred drug doesn't work.

Employee Experience: Communication and Appeals Matter as Much as the Savings

HR leaders sometimes underestimate the blowback when drugs disappear from the formulary overnight. Employees don't care about the difference between a $34,000/year Humira and its biosimilar unless the transition is clear, safe, and supported. I've seen employers lose more in lost trust and productivity than they saved on exclusions simply because they failed to communicate and support those affected.

Start member outreach early. Target communications to only those impacted, don't alarm the whole population. Provide clear, jargon-free explanations for why a drug is excluded, what the alternatives are, and how to appeal if there's a medical reason to stay on a non-covered medication. Use PBM or vendor resources like RxSaver.ai to help members compare prices if they have to pay out of pocket.

Make sure your appeals process is simple. Employees shouldn't need to jump through hoops to prove they've failed alternatives. Set up fast-track reviews for specialty cases, and monitor appeals trends, if you see a spike in a particular category, it may signal a formulary exclusion gone too far.

Finally, partner with your PBM to monitor member complaints and real-world outcomes. If forced switches start showing up in medical claims as ER visits or hospitalizations, revisit your exclusions. No dollar savings is worth a member ending up in the hospital, or HR spending their week on drug denial appeals.

Don't Go It Alone: When to Bring In the Experts

Contracting and data analysis are only half the battle. Knowing when an exclusion saves money versus when it simply shifts cost or creates risk takes experience. For tough calls, like excluding high-cost GLP-1s (Ozempic, Mounjaro) that now account for 10% of many plans’ total spend, bring in a pharmacy benefits consultant or actuary who can model not just claims savings, but the impact on stop-loss, employee engagement, and downstream health costs.

Regulations are evolving, too. If you're a self-funded ERISA plan, make sure your exclusions comply with nondiscrimination rules, and check that appeals meet regulatory requirements. For legal questions, always consult an ERISA attorney. For benchmarks, keep an eye on market intelligence tools like RxPBM.ai or current formulary changes tracked on RxNews.ai.

The best exclusion strategy is never copy/paste. It’s a balance between clinical logic, financial impact, and the very real human cost when someone loses a medication they count on. Sometimes, the right answer is to carve out a few high-abuse drugs. Other times, surgical cuts paired with strong member support move the needle. For most employers, a tailored, well-communicated exclusion policy beats a standard PBM "national" blocklist every time.